← Back to Search

Pembrolizumab for Pancreatic Cancer (UVA-PC-PD101 Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Craig L Slingluff, Jr
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2-4 years
Awards & highlights

UVA-PC-PD101 Trial Summary

This trial will study whether it is safe to give pembrolizumab in combination with neoadjuvant (before surgery) chemotherapy and radiation therapy for patients with resectable or borderline resectable pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer

UVA-PC-PD101 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2-4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2-4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Tumor Infiltrating Lymphocytes (TILs) per high powered field (hpf) in pancreatic tissue (resected tissue).
Safety: Incidence of Dose-Limiting Toxicities (DLTs)
Secondary outcome measures
Disease-free survival (DFS)
Overall survival (OS)
Response Rate (RR)

Side effects data

From 2024 Phase 2 trial • 57 Patients • NCT03004183
21%
Fatigue
13%
Nausea
11%
Back pain
9%
Shortness of Breath
9%
Anemia
9%
Abdominal pain
9%
Diarrhea
7%
Pneumonia
7%
Kidney Injury and/or Infection
7%
Dyspnea
7%
Weight Loss
5%
Malnutrition, Hypercalcemia and Weakness
5%
Pneumothorax
5%
Intractable pain, back pain, hip pain
5%
Activated partial thromboplastin time prolonged
4%
Pleural effusion
4%
Atrial fibrillation with rapid ventricular response
2%
Thrombocytopenia
2%
Respiratory failure
2%
Skin rash
2%
colitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Arm

UVA-PC-PD101 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Neodjuvant CRT + PembrolizumabExperimental Treatment2 Interventions
Standard neoadjuvant chemoradiation treatment (CRT) with pembrolizumab
Group II: Neoadjuvant CRTActive Control1 Intervention
Standard neoadjuvant chemoradiation treatment (CRT) alone
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved

Find a Location

Who is running the clinical trial?

Craig L Slingluff, JrLead Sponsor
23 Previous Clinical Trials
678 Total Patients Enrolled
Osama Rahma, MDStudy ChairDana-Farber Cancer Institute
1 Previous Clinical Trials
60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer
Craig L Slingluff, Jr 2015. "Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02305186.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top